Artesunate Therapy Alleviates Fracture-Associated Chronic Pain After Orthopedic Surgery by Suppressing CCL21-Dependent TREM2/DAP12 Inflammatory Signaling in Mice

Linlin Zhang; Nan Li; Haoyue Zhang; Yigang Wang; Tianyu Gao; Yuying Zhao; Guolin Wang; Yonghao Yu; Chunyan Wang; Yize Li

doi:10.3389/fphar.2022.894963

Artesunate Therapy Alleviates Fracture-Associated Chronic Pain After Orthopedic Surgery by Suppressing CCL21-Dependent TREM2/DAP12 Inflammatory Signaling in Mice

Front Pharmacol. 2022 Jun 2:13:894963. doi: 10.3389/fphar.2022.894963. eCollection 2022.

Authors

Linlin Zhang^{1

2}, Nan Li^{1

2}, Haoyue Zhang^{1

2}, Yigang Wang^{1

2}, Tianyu Gao^{1

2}, Yuying Zhao^{1

2}, Guolin Wang^{1

2}, Yonghao Yu^{1

2}, Chunyan Wang^{1

2}, Yize Li^{1

2}

Affiliations

¹ Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin, China.
² Tianjin Research Institute of Anesthesiology, Tianjin, China.

Abstract

Chronic pain after bone fracture and orthopedic surgery is often refractory to most analgesics currently in use, thus emphasizing the urgent need for improved therapeutic medications. Chemokine-dependent neuroinflammation is critical for excitatory synaptic plasticity and central nociception sensitization. Recent studies have focused on the inhibition of inflammatory responses by artesunate, the first anti-malaria drug extracted from artemisinin. The present study investigated the analgesic effects and potential targets of artesunate in a mouse model of chronic pain induced by tibial fracture and orthopedic surgery. Three injections of artesunate were intrathecally administered on a daily basis from days 4 to 6 after fracture. We reported that repetitive exposure to artesunate (10 and 100 μg but not 1 μg) dose-dependently prevented fracture-induced mechanical and cold allodynia. Moreover, single intrathecal injection of artesunate (100 μg) alleviated the established chronic pain on day 14 after fracture surgery. Intraperitoneal artesunate (10 and 50 mg kg^-1) therapy was effective against chronic fracture pain. Intriguingly, artesunate inhibited the upregulation of spinal chemokine CCL21, triggering receptor expressed on myeloid cells 2 (TREM2) and DNAX-activating protein of 12 kDa (DAP12) expressions and microglia activation in fracture mice. Furthermore, spinal CCL21 neutralization attenuated the severity of fracture-associated post-surgical pain. Exogenous CCL21-induced acute inflammatory pain was impaired by artesunate therapy. Additionally, the pharmacological blockage of TREM2 reduced recombinant CCL21-elicited behavioral hypernociception. The present findings demonstrate that artesunate therapy reduces the initiation and maintenance of fracture-associated chronic postoperative pain by inhibiting CCL21-dependent TREM2/DAP12 inflammatory signaling and microglia activation, thus suggesting that artesunate could emerge as a therapeutic strategy for fracture pain management.

Keywords: CCL21; DAP12; TREM2; artesunate; bone fracture; chronic pain; spinal cord.